Outcomes of Hydroxyurea Accessed via Various Means and Barriers Affecting Its Usage Among Children with Sickle Cell Anaemia in North-Western Tanzania

References

• Ilesanmi OO. Pathological basis of symptoms and crises in sickle cell disorder: implications for counseling and psychotherapy. Hematol Rev. 2010;2:10–22.
   Google Scholar
• Prithu Sundd MT, Gladwin EMN. Pathophysiology of Sickle Cell Disease. Physiol Behav. 2018;176:139–148.
   Google Scholar
• Therrell BLLloyd-Puryear MA, Ohene-Frempong K, et al. Empowering newborn screening programs in African countries through establishment of an international collaborative effort. J Community Genet. 2019;1:18.
   Google Scholar
• Ambrose EE, Makani J, Chami N, et al. High birth prevalence of sickle cell disease in Northwestern Tanzania. Pediatr Blood Cancer. 2018;65:e26735. doi:10.1002/pbc.26735
   Web of Science ®Google Scholar
• Ambrose EE, Smart LR, Charles M, et al. Geospatial mapping of sickle cell disease in northwest Tanzania: the Tanzania sickle surveillance study (TS3). Blood. 2018;132:3662. doi:10.1182/blood-2018-99-113939
   Web of Science ®Google Scholar
• Rwezaula S, Magesa PM, Mgaya J, et al. Newborn screening for hemoglobinopathies at Muhimbili National Hospital, Dar es Salaam–Tanzania. East Afr J Public Health. 2015;12:948–955.
   Google Scholar
• Saidi H, Smart LR, Kamugisha E, et al. Complications of sickle cell anaemia in children in Northwestern Tanzania. Hematology. 2016;21(4):248–256. doi:10.1080/10245332.2015.1101976
   PubMed Web of Science ®Google Scholar
• Wong TE, Brandow AM, Lim W, Lottenberg R. Update on the use of hydroxyurea therapy in sickle cell disease. Blood. 2014;124(26):3850–3857. doi:10.1182/blood-2014-08-435768
   PubMed Web of Science ®Google Scholar
• Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332(20):1317–1322. doi:10.1056/NEJM199505183322001
   PubMed Web of Science ®Google Scholar
• Cunningham-Myrie C, Abdulkadri A, Waugh A, et al. Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: a cost effectiveness analysis. Pediatr Blood Cancer. 2015;62(10):1862–1864. doi:10.1002/pbc.25563
   PubMed Web of Science ®Google Scholar
• Tshilolo L, Tomlinson G, Williams TN, et al. Hydroxyurea for children with sickle cell anemia in Sub-Saharan Africa. N Engl J Med. 2019;380(2):121–131. doi:10.1056/NEJMoa1813598
   PubMed Web of Science ®Google Scholar
• Opoka RO, Ndugwa CM, Latham TS, et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood. 2017. doi:10.1182/blood-2017-06-788935
   PubMedGoogle Scholar
• Candrilli SD, O’Brien SH, Ware RE, et al. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol. 2011;86(3):273–277. doi:10.1002/ajh.21968
   PubMed Web of Science ®Google Scholar
• Qureshi A, Kaya B, Pancham S, et al. Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease: a British Society for Haematology Guideline. Br J Haematol. 2018;181:460–475. doi:10.1111/bjh.15235
   PubMed Web of Science ®Google Scholar
• Ofakunrin AOD, S Okpe E, O Afolaranmi T, et al. Level of utilization and provider-related barriers to the use of hydroxyurea in the treatment of sickle cell disease patients in jos, north-central Nigeria. Afr Health Sci. 2021;21:765–774. doi:10.4314/ahs.v21i2.36
   PubMed Web of Science ®Google Scholar
• Power-Hays A, Ware RE. Effective use of hydroxyurea for sickle cell anemia in low-resource countries. Curr Opin Hematol. 2020;27(3):172–180. doi:10.1097/moh.0000000000000582
   PubMed Web of Science ®Google Scholar
• Kilonzi M, Mlyuka HJ, Felician FF, et al. Barriers and Facilitators of Use of Hydroxyurea among Children with Sickle Cell Disease: experiences of Stakeholders in Tanzania. Hemato. 2021;2(4):713–726. doi:10.3390/hemato2040048
   Google Scholar
• Ware RE. Optimizing hydroxyurea therapy for sickle cell anemia. Hematol Am Soc Hematol Educ Progr. 2015;2015:436–443. doi:10.1182/asheducation.V2015.1.436.3917688
   PubMedGoogle Scholar
• Nahavandi M, Tavakkoli F, Wyche MQ, et al. Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea. Br J Haematol. 2002;119(3):855–857. doi:10.1046/j.1365-2141.2002.03919.x
   PubMed Web of Science ®Google Scholar
• Cokic VP, Andric SA, Stojilkovic SS, Noguchi CT, Schechter AN. Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells. Blood. 2008;111:1117. doi:10.1182/blood-2007-05-088732
   PubMed Web of Science ®Google Scholar
• Davies SC, Gilmore A. The role of hydroxyurea in the management of sickle cell disease. Blood Rev. 2003;17:99–109. doi:10.1016/S0268-960X(02)00074-7
   PubMed Web of Science ®Google Scholar
• Conran N, Belcher JD. Inflammation in sickle cell disease. Clin Hemorheol Microcirculat. 2018. doi:10.3233/CH-189012
   PubMed Web of Science ®Google Scholar
• Badawy SM, Thompson AA, Penedo FJ, et al. Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease. Eur J Haematol. 2017;98:608–614. doi:10.1111/ejh.12878
   PubMed Web of Science ®Google Scholar
• Adeyemo TA, Diaku-Akinwunmi IN, Ojewunmi OO, Bolarinwa AB, Adekile AD. Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria. Hemoglobin. 2019;43:188–192. doi:10.1080/03630269.2019.1649278
   PubMed Web of Science ®Google Scholar
• Okocha EC, Gyamfi J, Ryan N, et al. Barriers to therapeutic use of hydroxyurea for sickle cell disease in Nigeria: a cross-sectional survey. Front Genet. 2022;12:2834. doi:10.3389/fgene.2021.765958
   Web of Science ®Google Scholar
• Abdullahi SU, Jibir BW, Bello-Manga H, et al. Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, Phase 3 trial. Lancet Haematol. 2022;9:e26–e37. doi:10.1016/S2352-3026(21)00368-9
   PubMed Web of Science ®Google Scholar
• Galadanci NA, Abdullahi SU, Ali Abubakar S, et al. Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: final results of the SPIN trial. Am J Hematol. 2020;95:E247. doi:10.1002/ajh.25900
   PubMed Web of Science ®Google Scholar
• Costa E, Tibalinda P, Sterzi E, et al. Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (HASTE): how to meet major health needs at a reasonable cost. Am J Hematol. 2021;96:E2–E5. doi:10.1002/ajh.26007
   PubMed Web of Science ®Google Scholar